Evidence map›Paper›PMID 40215232›Full record

ArticlePLoS biology2025

Vps34-orchestrated lipid signaling processes regulate the transitional heterogeneity and functional adaptation of effector regulatory T cells.

Erienne G Norton, Nicole M Chapman, Hao Shi, Xiaoxi Meng, Hongling Huang, Anil Kc, Sherri Rankin, Jordy Saravia, Sujing Yuan, Haoran Hu and 2 more

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Erienne G NortonDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Nicole M ChapmanDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Hao ShiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Xiaoxi MengDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Hongling HuangDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Anil KcDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Sherri RankinDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Jordy SaraviaDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Sujing YuanDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Haoran HuDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Peter VogelDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.
Hongbo ChiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.

Funding

Integrating systems immunology with immunometabolism and cancer immunityR35CA253188 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2021 to 2026
$6.0M
Regulation of TH17 plasticity and stemness by mTORC1R01AI131703 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2018 to 2026
$4.1M
Transcriptional and metabolic heterogeneity in T cell differentiationR01AI140761 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2018 to 2026
$3.9M
Metabolic checkpoint in dendritic cell subsets and adaptive immunityR37AI105887 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2019 to 2026
$3.6M
Bidirectional signaling in T cell differentiationR01AI150241 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2019 to 2026
$3.3M
Nutrient sensing and lysosomal signaling in regulatory T cells and immune toleranceR01AI150514 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHI, HONGBO · 2019 to 2023
$2.2M
Metabolic signaling dictates context-dependent Treg cell functional heterogeneityF31AI186413 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC · PI NORTON, ERIENNE GRACE · 2024 to 2025
$68k
NCI NIH HHS R35 CA253188NIAID NIH HHS F31 AI186413NIAID NIH HHS R01 AI131703NIAID NIH HHS R01 AI140761NIAID NIH HHS R01 AI150241NIAID NIH HHS R01 AI150514NIAID NIH HHS R37 AI105887
6 · The paper itself

Abstract

Regulatory T cell (Treg) heterogeneity exists in lymphoid and non-lymphoid tissues, but we have limited understanding of context-dependent functions and spatiotemporal regulators of heterogenous Treg states, especially during perinatal life when immune tolerance is established. Here, we revealed that the class III PI3K Vps34 orchestrates effector Treg (eTreg) transitional heterogeneity during perinatal life. We found that loss of Vps34 reduced terminal eTreg accumulation in lymphoid tissues, associated with decreased Treg generation in non-lymphoid tissues and development of an early-onset autoimmune-like disease. After perinatal life, Vps34-deficient eTreg accumulation was further impaired due to reduced cell survival, highlighting temporal regulation of eTreg heterogeneity and maintenance by Vps34. Accordingly, inhibition of Vps34 in mature Tregs disrupted immune homeostasis but boosted anti-tumor immunity. Mechanistically, multiomics profiling approaches uncovered that Vps34-orchestrated transcriptional and epigenetic remodeling promotes terminal eTreg programming. Further, via genetic deletion of the Vps34-interacting proteins Atg14 or Uvrag in Tregs, we established that Atg14 but not Uvrag was required for the overall survival, but not terminal differentiation, of eTregs, suggesting that autophagy but not endocytosis partly contributed to Vps34-dependent effects. Accordingly, mice with Treg-specific loss of Atg14, but not Uvrag, had moderately disrupted immune homeostasis and reduced tumor growth, with Vps34- or Atg14-dependent gene signatures also being elevated in intratumoral Tregs from human cancer patients. Collectively, our study reveals distinct Vps34-orchestrated signaling events that regulate eTreg heterogeneity and functional adaptation and the pathophysiological consequences on autoimmunity versus anti-tumor immunity.

Indexed as

Class III Phosphatidylinositol 3-KinasesLipid MetabolismT-Lymphocytes, RegulatoryAnimalsAutophagyAutophagy-Related ProteinsCell DifferentiationHumansImmune ToleranceMiceMice, Inbred C57BLMice, KnockoutSignal TransductionAutophagy-Related ProteinsClass III Phosphatidylinositol 3-Kinases

Identifiers

PMID40215232
PMCPMC11990774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.